Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
about
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironmentEarly sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyMultikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibSorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysisThe discovery and development of sorafenib for the treatment of thyroid cancer.Lack of association between excretion of sorafenib in sweat and hand-foot skin reactionThe influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot studyPazopanib: therapeutic developments.Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature.Toxicity of sorafenib: clinical and molecular aspects.Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.Sorafenib-associated hand-foot syndrome in Japanese patients.Sorafenib in melanoma.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.The adverse effects of sorafenib in patients with advanced cancers.Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.PharmGKB summary: sorafenib pathways.Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy.Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.Array of cutaneous adverse effects associated with sorafenibFractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
P2860
Q27335748-1E7F9A0B-5028-469E-A606-418A0C957A5DQ28482219-F79F1F9E-3374-465F-8BB4-F24ECAD0A11AQ30250106-6D3E41A5-6E35-466C-BD7B-21F1D847C260Q33408049-84BE0669-A531-48CD-83E6-133FD263AB95Q34036032-58709D18-231B-462B-8452-D6096AE5A6A6Q34042709-AD383850-FE88-4D96-BA66-8BD93E91866FQ34363435-BA610CF2-A2F2-45BC-A15B-292242B57B11Q34973732-9FDD51F0-9B37-4CC0-9162-62C8992333BDQ35104052-5F27365D-254D-4FCC-B87C-3DF33A75014DQ35419004-527F6EB8-FA45-474E-9D48-BBA61EDF0D12Q35553882-48AC5E72-5356-4C18-AD87-72F8C26E094AQ35599769-939E8833-E217-4629-A27B-AD407982A0B2Q35891218-9F05125F-D465-40F1-AA13-97F02C58CB91Q36078348-B4C0311E-C530-4FBD-8EC6-53981E635147Q36112023-39615203-7629-4A54-9901-09D7986012A7Q36251480-F0B16989-D25C-4642-925C-E7C721AC7287Q36263304-40BD9AA9-0271-4196-A106-8D46C8B7757DQ36525237-31832070-B7CF-439B-853F-875AD304DC4DQ36528151-1310EFF0-3BD6-44F4-A838-34F2DDD5586FQ37152133-25F15226-3EFE-479D-8E18-77D6A5122C7DQ37642770-946BB9BC-BC5C-48E3-B363-5D4BEF8A46EFQ37663028-B7710385-C014-45F4-8B5A-E19C68953DABQ37676226-E50944D7-6956-4AE6-B024-445E6396D4B9Q37683755-483A78E3-79FF-4964-BDA2-5570555D76E6Q37845916-E5835E9C-393E-4C01-8698-093D94992AF9Q37990977-073ECA12-D494-4791-9C75-2C3CDD27DF4CQ38076349-DC029F35-7965-4F4D-8B05-B19AA8CBF31EQ38201503-307971DC-6050-40D3-8666-7E0DB9BFF8A0Q38286308-5FDF8237-85BE-4EC5-9E2F-683A0A3698CBQ38368008-798965B3-D4CA-44AD-BBB6-ED7A91477142Q38864682-FBDF2EA2-D3EB-4C73-B776-C5330D02E5ECQ38886929-097F88E9-516E-4B27-AC4E-809E04B75FCFQ39320160-D33F2475-BB5F-4EAF-AFEA-6B9139589703Q39379568-E2F17F5A-0088-4223-AFFB-380150930A92Q39555847-2ACC231B-7483-4536-8ACB-68F573D4B3F1Q40751962-B1A5AE3C-B9B5-4794-A152-1F9CEA02EDC3Q41229554-553527A4-4391-47BB-BFE8-52DF8EF86081Q42556141-82A9E0FF-10F3-426F-AF7C-1ED7BE40AE89Q44252023-316FFBDE-C7FB-4120-B4B1-76230D0444D5Q45766668-9BE23DBD-4834-4EF8-B016-48EED548E76C
P2860
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hand-foot skin reaction increa ...... thelial growth factor therapy.
@en
Hand-foot skin reaction increa ...... thelial growth factor therapy.
@nl
type
label
Hand-foot skin reaction increa ...... thelial growth factor therapy.
@en
Hand-foot skin reaction increa ...... thelial growth factor therapy.
@nl
prefLabel
Hand-foot skin reaction increa ...... thelial growth factor therapy.
@en
Hand-foot skin reaction increa ...... thelial growth factor therapy.
@nl
P2093
P2860
P1476
Hand-foot skin reaction increa ...... othelial growth factor therapy
@en
P2093
Elise C Kohn
Lokesh Jain
Maria L Turner
Martin Gutierrez
Nilofer S Azad
Seth M Steinberg
William D Figg
William L Dahut
P2860
P304
P356
10.1158/1078-0432.CCR-08-1141
P407
P577
2009-02-01T00:00:00Z